CytoDyn Inc.
Close on Oct 19, 2026
- Market cap
- $345.56M
- P/E (TTM)
- –
- Dividend yield
- –
About CytoDyn
Pharmaceutical Preparations, SIC 2834
CytoDyn Inc. is a clinical-stage biotechnology firm that focuses on developing and potentially commercializing targeted therapies for oncology indications. Its primary investigational asset is leronlimab, a humanized monoclonal antibody designed to bind the CCR5 receptor, which is associated with tumor development, cellular migration, and immune modulation. The company investigates leronlimab primarily for solid tumors, including relapsed or refractory metastatic colorectal cancer and metastatic triple-negative breast cancer, alongside preclinical evaluations for glioblastoma multiforme. As a development-stage biopharmaceutical organization without approved commercial products, CytoDyn does not sell therapies to conventional commercial customers; instead, its clinical programs serve cancer patients enrolled in trials and expanded access protocols.
The company conducts its operations and clinical trials across several sites in the United States, with active patents and applications spanning the United States and international territories. Its principal business office is located in Vancouver, Washington.
Summary of the business section of CytoDyn's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CytoDyn Inc.
- Founded
- 2002
- Headquarters
- Vancouver, WA
- Address
- 1111 Main Street, Suite 660 98660
- Phone
- (360) 980-8524
- Website
- cytodyn.com
- Employees
- 14, May 31, 2026
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- May 31
- Auditor
- CBIZ CPAs P.C., Hartford, CT
Stock & identifiers
- Ticker
- CYDY
- Exchange
- OTC
- IPO date
- Dec 13, 2006
- Shares outstanding
- 1.38B, Jun 30, 2026
- Public float
- $417.68M, Nov 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1175680
- CUSIP
- 23283M101
- ISIN
- US23283M1018
- LEI
- 529900Q4JAVBX3H8RF98
- EIN
- 75-3056237
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Robert E. Hoffman | Chief Financial Officer | – |
| Tyler Blok | Chief Legal Officer | 250 |
| Jacob P. Lalezari | Chief Executive Officer | – |
| Stephen M. Simes | Director | – |
| Karen J. Brunke | Director | – |
| Lishomwa C. Ndhlovu | Director | – |
| Ryan Dunlap | Director | – |
| Tanya Durkee Urbach | Director | 162,113 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Antonio Migliarese | $0 | $0 | $1.65M | $88 | – |
| FY2026 Cyrus Arman | $0 | $0 | $1.65M | $88 | – |
| FY2026 Jacob Lalezari | $1.83M | $1.54M | $1.65M | $88 | – |
| FY2025 Antonio Migliarese | $0 | $0 | $499.01K | $210 | – |
| FY2025 Cyrus Arman | $0 | $0 | $499.01K | $210 | – |
| FY2025 Jacob Lalezari | $783.85K | $1.31M | $499.01K | $210 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of July 31, 2026, we had 14 employees, as well as a number of independent consultants and other individuals assisting us with the Company’s regulatory, quality and medical matters.”
Corporate history
Events identified from SEC filings